EUVIMEDEUVIMED entdecken
Crossref

CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE

Мaryana М Rоsul, Мyroslava М Bletskan, Nataliya V Ivano, Marina O Korabelschykova, Svitlana O Rudakova

Wiadomości Lekarskie · 2023

DOI: 10.36740/wlek202303130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Wiadomości Lekarskie, 2023. Verfasst von Мaryana М Rоsul und 4 weiteren Autor:innen. Beteiligte Einrichtung: STATE HIGHER EDUCATIONAL ESTABLISHMENT "UZHHOROD NATIONAL UNIVERSITY", UZHHOROD, UKRAINE. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Heart Failure, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim: To study the possibilities of increasing the effectiveness of treatment and improving the prognosis of patients with various phenotypes of heart failure when using empagliflozin. Materials and methods: The analysis of the data regarding the results of existing studies evaluating the clinical benefit and safety of empagliflozin in patients with various phenotypes of heart failure has been conducted. Conclusions: In the EMPA-REG OUTCOME study, empagliflozin has demonstrated the ability to improve cardiorenal outcomes and reduce the risk of hospitalization for heart failure in patients with diabetes. The results of the studies (EMPEROR-Preserved, EMPEROR-Reduced, EMPULSE) have shown the clinical advantages of empagliflozin over traditional heart failure therapy, manifested by a reduction in mortality and the number of hospitalizations for heart failure, as well as improvement in quality of life indicators. The clinical benefits of using empagliflozin were observed in patients with chronic heart failure with different left ventricular ejection fraction, as well as in patients with acute heart failure. Empagliflozin is a sodium-glucose co-transporter 2 inhibitor with a convincing evidence base for the treatment of all categories of patients with chronic heart failure, regardless of diabetes status. The results of the conducted studies indicate the unconditional benefit of early initiation of empagliflozin therapy in patients with both chronic and acute heart failure after the stabilization of their condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsHumansStroke VolumeQuality of LifeVentricular Function, LeftTreatment OutcomeChronic DiseaseBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

empagliflozinheart failuresodium-glucose co-transporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsempagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • STATE HIGHER EDUCATIONAL ESTABLISHMENT "UZHHOROD NATIONAL UNIVERSITY", UZHHOROD, UKRAINE.

Zitieren

APA

Rоsul, М. М., Bletskan, М. М., Ivano, N. V., Korabelschykova, M. O., & Rudakova, S. O. (2023). CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE. Wiadomości Lekarskie. https://doi.org/10.36740/wlek202303130

Vancouver

Rоsul ММ, Bletskan ММ, Ivano NV, Korabelschykova MO, Rudakova SO. CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE. Wiadomości Lekarskie. 2023. doi:10.36740/wlek202303130

BibTeX
@article{Rsul2023,
  author = {Rоsul, Мaryana М and Bletskan, Мyroslava М and Ivano, Nataliya V and Korabelschykova, Marina O and Rudakova, Svitlana O},
  title = {CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE},
  journal = {Wiadomości Lekarskie},
  year = {2023},
  doi = {10.36740/wlek202303130}
}
Kostenlos starten →